Scheduled Maintenance. MDBriefCase will be down on Sunday, November 27, 2022.
We are busy updating our website and learning platform to enhance your learning experience. We’ll be back up and running again before long, so please try again soon.

RSV and Infants: What You Need to Know

Nov 1st, 2023 | 12:00 PM – 1:00 PM EST

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTI) in children globally, with cases of severe RSV disease occurring in infants less than 6 months of age. RSV is also the leading cause of infant hospitalizations in Canada. Due to the limited therapeutic options available to manage RSV illness, the focus has been on disease prevention. At present, there is no vaccine available to prevent RSV. Monoclonal antibodies provide temporary passive protection. Palivizumab has been in use for over 20 years in Canada to protect infants at high risk of severe disease. Nirsevimab has recently been authorized for the protection of all infants against RSV disease.

Upon completion of this program, participants will be able to:

  • Recognize the prevalence and burden of RSV disease in all infants
  • Explain the role of monoclonal antibodies for protection against preventable disease
  • Apply approved RSV immunoprophylaxis in clinical practice
  • Employ strategies to discuss RSV immunoprophylaxis for all infants and children

Can’t attend? Register to receive a notification once the webinar is available on-demand.

This webinar will feature:

Cora-Constantinescu-headshot v2

Cora Constantinescu


John DP

John Yaremko



Vivien Brown


Registration Form

Select Which Webinars You’d Like to Attend